NCT03810742View on ClinicalTrials.gov

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

May 4, 2022

Study Completion Date

October 25, 2023

Conditions
Refractory Solid Tumors
Interventions
DRUG

Nanoliposomal Irinotecan

Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)

Trial Locations (2)

Unknown

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Sponsors

Lead Sponsor

PharmaEngine
All Listed Sponsors
lead

PharmaEngine

INDUSTRY

NCT03810742 - Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors | Biotech Hunter | Biotech Hunter